Cobolimab
- Generic Name
- Cobolimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2022215-65-0
- Unique Ingredient Identifier
- 3K5H4TX2KP
- Background
Cobolimab is under investigation in clinical trial NCT04655976 (Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 95
- Registration Number
- NCT06521567
- Locations
- πΊπΈ
GSK Investigational Site, Iowa City, Iowa, United States
Dostarlimab and Cobolimab in Advanced Cervical Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Meghan Shea
- Target Recruit Count
- 66
- Registration Number
- NCT06238635
- Locations
- πΊπΈ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 758
- Registration Number
- NCT04655976
- Locations
- π¬π§
GSK Investigational Site, Manchester, United Kingdom
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 244
- Registration Number
- NCT04446351
- Locations
- π°π·
GSK Investigational Site, Seoul, Korea, Republic of
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 829
- Registration Number
- NCT02723955
- Locations
- πͺπΈ
GSK Investigational Site, Sevilla, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2024. All Rights Reserved by MedPath